Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 4/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.33 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14008528 | 0.87 | SMYD3 (0.37) | CTSCSMYD3PLD1PLATTP53 | |
| SCHEMBL4440513 | 0.79 | SMYD3 (0.47) | CTSCSMYD3PLD1OPRL1 | |
| SCHEMBL14146291 | 0.77 | PLD1 (0.39) | PLD1TP53OPRM1OPRL1 | |
| SCHEMBL4433059 | 0.76 | PLD1 (0.38) | PLD1AROPRM1OPRL1 | |
| SCHEMBL4444437 | 0.76 | PLD1 (0.38) | CTSCPLD1AROPRM1OPRL1 | |
| SCHEMBL4439004 | 0.76 | PLD1 (0.38) | CTSCPLD1AROPRM1OPRL1 | |
| SCHEMBL5004185 | 0.76 | PLD1 (0.38) | CTSCPLD1AROPRM1OPRL1 | |
| SCHEMBL4437442 | 0.76 | PLD1 (0.38) | PLD1PARP2OPRM1OPRL1 | |
| SCHEMBL4445741 | 0.75 | SMN1; SMN2 (0.44) | PLD1OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL4440163 | 0.75 | PLD1 (0.38) | PLD1AROPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | CTSC 299/4885SMYD3 3617/4885PLD1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.